Skip to main content

Table 1 Baseline clinical characteristics and parameters of the patients

From: Plasma erythropoietin level and heart failure in patients undergoing peritoneal dialysis: a cross-sectional study

Total, n

39

Female, n (%)

11 (28.2)

Age (years)

63.23 ± 12.52

BMI (kg/m2)

23.81 ± 3.70

Diatbetes, n (%)

25 (64.1)

Diabetic nephritis as primary disease, n (%)

19 (48.7)

Nephrosclerosis, n (%)

5 (12.8)

PD vintage (months)

19.41 ± 21.73

D/P ratio

0.687 ± 0.143

D/D0 ratio

0.384 ± 0.106

Urinary volume (ml/day)

899.2 ± 452.8

Dialysate dose (ml/day)

5051.3 ± 1601.0

RASi, n (%)

28 (71.8)

Beta blocker, n (%)

9 (23.1)

Statin, n (%)

15 (38.5)

Diuretic (%)

30 (76.9)

Iron supplementation, n (%)

9 (23.1)

IVSd (mm)

9.795 ± 2.166

PWd (mm)

9.974 ± 2.194

LVDd (mm)

48.54 ± 7.181

LVDs (mm)

32.18 ± 7.904

LVMI (g/m2)

120.7 ± 38.99

EF (%)

61.62 ± 13.28

E/A

0.747 ± 0.250

Cardiac index

3.062 ± 1.334

Peritoneal Kt/V urea

4.825 ± 1.679

Renal Kt/V urea

3.816 ± 3.679

Weekly Kt/V urea

1.711 ± 0.757

Peritoneal CCr (L/week/1.73 m2)

3.623 ± 1.569

Renal CCr (L/week/1.73 m2)

5.771 ± 5.690

Weekly CCr (L/week/1.73 m2)

66.65 ± 34.43

Cr at starting PD (mg/dL)

7.368 ± 2.893

eGFR at starting PD (mL/ min/1.73 m2)

6.885 ± 2.293

ESA dose (μg/month)

127.3 ± 78.46

Plasma erythropoietin (mIU/mL)

7.933 ± 5.494

RBC (*104/μL)

360.7 ± 43.23

Hb (g/dL)

10.72 ± 1.266

Ht (%)

32.76 ± 3.805

Reticulocyte (‰)

10.33 ± 5.075

Fe (μg/dL)

88.18 ± 30.58

TIBC (μg/dL)

248.4 ± 41.77

Ferritin (ng/mL)

158.9 ± 153.4

TSAT

0.360 ± 0.133

CTR (%)

49.57 ± 5.435

NT-proBNP (pg/mL)

11839.8 ± 21293.2

Lactate (mg/dL)

10.85 ± 5.386

Ca (mg/dL)

8.438 ± 0.821

P (mg/dL)

5.818 ± 1.612

iPTH (pg/mL)

250.3 ± 117.4

Na (mEq/L)

138.8 ± 3.639

K (mEq/L)

4.564 ± 0.788

Cl (mEq/L)

101.6 ± 4.951

BUN (mg/dL)

62.20 ± 13.93

Cr (mg/dL)

9.591 ± 3.438

TP (g/dL)

6.241 ± 0.612

Alb (g/dL)

3.269 ± 0.404

CRP (mg/dL)

0.459 ± 2.144

sβ2MG (mg/L)

24.43 ± 9.657

Venous pH

7.360 ± 0.040

NYHA classification

 I, n (%)

30 (76.9)

 II, n (%)

9 (23.1)

 III and IV

None

  1. BMI body mass index, RASi renin–angiotensin system inhibitor, PD peritoneal dialysis, D/P ratio dialysate creatinine to plasma creatinine ratio, D/D ratio dialysate glucose to initial dialysate glucose ratio, RASi intake of renin–angiotensin system inhibitor, IVSd interventricular septum diameter, PWd posterior wall diameter, LVDd left ventricular end-diastolic diameter, LVDs left ventricular end-systolic diameter, LVMI left ventricular mass index, EF left ventricle ejection fraction, E/A early to late diastolic transmitral flow velocity, CCr creatinine clearance, eGFR estimated glomerular filtration rate, ESA erythropoiesis-stimulating agent, RBC red blood cell, Hb hemoglobin, Ht hematocrit, Fe serum ferrum, TIBC total iron binding capacity, CTR cardiothoracic ratio, NT-proBNP N-terminal pro-brain natriuretic peptide, Ca serum calcium, P serum phosphorus, iPTH intact parathyroid hormone, Na serum sodium, K serum potassium, Cl serum chlorine, BUN blood urea nitrogen, Cr serum creatinine, TP serum total protein, Alb serum albumin, CRP C-reactive protein, sβ2MG serum beta 2 microglobulin, NYHA the New York Heart Association